Skip to content
10-Q

Quarterly Report

Skye Bioscience, Inc. SKYE

0001628280-26-033417

← back to feed
Filed
May 11, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 8, 2026 35.14M sh
Shares Diluted Q1 2026 · Mar 31, 2026 39.68M sh
Shares Diluted Q1 2026 · Mar 31, 2025 39.65M sh
Capex Q1 2026 · Mar 31, 2026 $0
Capex Q1 2026 · Mar 31, 2025 $6.31K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$8.56M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$9.19M
Short Term Investments Q1 2026 · Mar 31, 2026 $8.96M
Short Term Investments Q1 2026 · Dec 31, 2025 $19.85M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $8.15M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $5.88M
Stockholders Equity Q1 2026 · Mar 31, 2026 $9.01M
Stockholders Equity Q1 2026 · Dec 31, 2025 $20.02M
Stockholders Equity Q1 2026 · Mar 31, 2025 $59.25M
Stockholders Equity Q1 2026 · Dec 31, 2024 $68.15M
Current Liabilities Q1 2026 · Mar 31, 2026 $10.4M
Current Liabilities Q1 2026 · Dec 31, 2025 $8.21M
Total Liabilities Q1 2026 · Mar 31, 2026 $10.4M
Total Liabilities Q1 2026 · Dec 31, 2025 $8.29M
Current Assets Q1 2026 · Mar 31, 2026 $18.57M
Current Assets Q1 2026 · Dec 31, 2025 $27.09M
Total Assets Q1 2026 · Mar 31, 2026 $19.42M
Total Assets Q1 2026 · Dec 31, 2025 $28.31M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.32
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.28
Eps Basic Q1 2026 · Mar 31, 2026 −$0.32
Eps Basic Q1 2026 · Mar 31, 2025 −$0.28
Sga Expense Q1 2026 · Mar 31, 2026 $4.74M
Sga Expense Q1 2026 · Mar 31, 2025 $4.56M
Net Income Q1 2026 · Mar 31, 2026 −$12.51M
Net Income Q1 2026 · Mar 31, 2025 −$11.1M
Operating Income Q1 2026 · Mar 31, 2026 −$12.67M
Operating Income Q1 2026 · Mar 31, 2025 −$11.76M